非结合单克隆抗体 (mAb) 彻底改变了多种癌症的治疗方法。其中一些单克隆抗体通过直接细胞毒性作用促进恶性细胞的清除。最近，抗体依赖性细胞吞噬作用 (ADCP) 已被认为是许多广泛使用的 mAb 的主要作用机制，包括抗 CD20（利妥昔单抗、obinutuzumab）、抗 HER2（曲齐珠单抗）和抗 CD38 （达雷妥尤单抗）。然而，作为单一疗法，这些 ADCP 诱导单克隆抗体在体内产生的细胞毒性水平不足，并且没有疗效。因此，这些单克隆抗体最有效地用于联合疗法。许多患者明显产生耐药性，进一步阻碍了这些单克隆抗体的功效。在这里，我们将探讨 ADCP 在癌症免疫治疗中的作用，并讨论可能限制 ADCP 诱导单克隆抗体体内功效的关键因素。最后，我们将讨论当前用于克服这些限制的见解和方法。

Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of many types of cancer. Some of these mAbs promote the clearance of malignant cells via direct cytotoxic effects. More recently, antibody-dependent cellular phagocytosis (ADCP) has been appreciated as a major mechanism of action for a number of widely-used mAbs, including anti-CD20 (rituximab, obinutuzumab), anti-HER2 (trazituzumab), and anti-CD38 (daratumumab). However, as a monotherapy these ADCP-inducing mAbs produce insufficient levels of cytotoxicity in vivo and are not curative. As a result, these mAbs are most effectively used in combination therapies. The efficacy of these mAbs is further hampered by the apparent development of drug resistance by many patients. Here we will explore the role of ADCP in cancer immunotherapy and discuss the key factors that could limit the efficacy of ADCP-inducing mAbs in vivo. Finally, we will discuss current insights and approaches being applied to overcome these limitations.